Report looks at concerns surrounding labeling, adulteration, drug interactions, overdose and toxicity, and it also examines regulatory frameworks across various countries and regions.
According to a press release issued by the FDA, the agency is postponing most foreign inspections through April, effective immediately, in response to the COVID-19 outbreak. Inspections outside the U.S. deemed mission-critical will still be considered on a case-by-case basis.
